To appraise the clinical and cost-effectiveness of Nivolumab in combination with relatlimab within its marketing authorisation for melanoma
Status In progress
Decision Selected
Process STA 2018
ID number 1612


Key events during the development of the guidance:

Date Update
10 December 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
08 May 2019 In progress. Referred 17 October 2018

For further information on our processes and methods, please see our CHTE processes and methods manual